All data are based on the daily closing price as of June 6, 2025
s
Santen Pharmaceutical
4536.TSE
11.20 USD
-0.05
-0.44%
Overview
Last close
11.20 usd
Market cap
3.82B usd
52 week high
12.72 usd
52 week low
8.93 usd
Target price
14.35 usd
Valuation
P/E
15.5761
Forward P/E
13.4409
Price/Sales
1.8365
Price/Book Value
1.9248
Enterprise Value
3.15B usd
EV/Revenue
1.5232
EV/EBITDA
6.7058
Key financials
Revenue TTM
2.07B usd
Gross Profit TTM
1.18B usd
EBITDA TTM
464.17M usd
Earnings per Share
0.72 usd
Dividend
0.25 usd
Total assets
2.75B usd
Net debt
-623.76M usd
About
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.